Allogene Therapeutics Announces Retirement of Chief Financial Officer
I'm LongbridgeAI, I can summarize articles.Allogene Therapeutics announced that Executive Vice President and CFO Geoffrey Parker will retire, effective November 6, 2026. This leadership transition may impact financial stewardship as the company navigates funding needs in the competitive biotech sector. Meanwhile, analyst ratings on ALLO stock remain mixed, with a Buy rating at $14.00 target, while TipRanks' AI Analyst Spark rates it Neutral due to weak financial performance despite improving burn trends.
Allogene Therapeutics ( (ALLO) ) has shared an announcement.
On August 31, 2026, Allogene Therapeutics, Inc. announced that Geoffrey Parker, its Executive Vice President and Chief Financial Officer, provided notice of his retirement from all positions at the company, effective November 6, 2026. The planned departure of the principal financial officer marks a significant leadership transition that may affect financial stewardship and strategic execution as Allogene navigates funding needs and investor expectations in the competitive biotech sector.
The most recent analyst rating on (ALLO) stock is a Buy
with a $14.00 price target.
To see the full list of analyst forecasts on Allogene Therapeutics stock,
see the ALLO Stock Forecast page.
Spark’s Take on ALLO Stock
According to Spark, TipRanks’ AI Analyst, ALLO is a Neutral.
The score is primarily held back by very weak financial performance (large losses and ongoing negative free cash flow), only partly offset by a manageable balance sheet and improving burn trends. Technicals are neutral-to-mildly positive, while valuation is constrained by negative earnings and no dividend. The latest earnings call added meaningful support due to clear milestones, regulatory validation, and encouraging early signals, but clinical, safety, and statistical readout risks remain.
To see Spark’s full report on ALLO stock,
click here.
More about Allogene Therapeutics
Allogene Therapeutics, Inc. is a biotechnology company focused on developing allogeneic cell therapies, leveraging off‑the‑shelf CAR T treatments for cancer and other serious diseases. Operating in the biopharmaceutical sector, the company targets advanced oncology indications and relies heavily on executive leadership to manage its capital-intensive R&D and clinical programs.
Average Trading Volume: 7,539,727
Technical Sentiment Signal: Sell
Current Market Cap: $691M
For a thorough assessment of ALLO stock, go to TipRanks’ Stock Analysis page.